nemolizumab atopic
Selected indexed studies
- Nemolizumab for atopic dermatitis. (Drugs Today (Barc), 2022) [PMID:35412530]
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. (N Engl J Med, 2020) [PMID:32640132]
- Nemolizumab for the treatment of atopic dermatitis. (J Dermatolog Treat, 2025) [PMID:41111453]
_Worker-drafted node — pending editorial review._
Connections
nemolizumab atopic is a side effect of
Sources
- Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. (2020) pubmed
- Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence. (2026) pubmed
- Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. (2020) pubmed
- Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. (2022) pubmed
- Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. (2024) pubmed
- Nemolizumab for atopic dermatitis. (2022) pubmed
- Nemolizumab for the treatment of atopic dermatitis. (2025) pubmed
- The role of nemolizumab in the treatment of atopic dermatitis for the adult population. (2024) pubmed
- Clinical factors predicting nemolizumab response in atopic dermatitis. (2025) pubmed
- Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis. (2025) pubmed